CA2835932C - Processes and intermediates for preparing anti-hiv agents - Google Patents

Processes and intermediates for preparing anti-hiv agents Download PDF

Info

Publication number
CA2835932C
CA2835932C CA2835932A CA2835932A CA2835932C CA 2835932 C CA2835932 C CA 2835932C CA 2835932 A CA2835932 A CA 2835932A CA 2835932 A CA2835932 A CA 2835932A CA 2835932 C CA2835932 C CA 2835932C
Authority
CA
Canada
Prior art keywords
compound
formula
salt
aryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2835932A
Other languages
English (en)
French (fr)
Other versions
CA2835932A1 (en
Inventor
Richard Hung Chiu Yu
Brandon Heath Brown
Richard P. Polniaszek
Benjamin R. Graetz
Keiko Sujino
Duong Duc-Phi Tran
Alan Scott Triman
Kenneth M. Kent
Steven Pfeiffer
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CA2835932A1 publication Critical patent/CA2835932A1/en
Application granted granted Critical
Publication of CA2835932C publication Critical patent/CA2835932C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4071Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4075Esters with hydroxyalkyl compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44Amides thereof
    • C07F9/4434Amides thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4449Esters with hydroxyaryl compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/173Purine radicals with 2-deoxyribosyl as the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CA2835932A 2011-05-19 2012-05-18 Processes and intermediates for preparing anti-hiv agents Active CA2835932C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161488133P 2011-05-19 2011-05-19
US61/488,133 2011-05-19
PCT/US2012/038615 WO2012159047A1 (en) 2011-05-19 2012-05-18 Processes and intermediates for preparing anti-hiv agents

Publications (2)

Publication Number Publication Date
CA2835932A1 CA2835932A1 (en) 2012-11-22
CA2835932C true CA2835932C (en) 2020-03-24

Family

ID=46208163

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2835932A Active CA2835932C (en) 2011-05-19 2012-05-18 Processes and intermediates for preparing anti-hiv agents

Country Status (10)

Country Link
US (5) US8987437B2 (https=)
EP (3) EP3199537B1 (https=)
JP (4) JP5951757B2 (https=)
AR (1) AR086492A1 (https=)
AU (4) AU2012255029B2 (https=)
CA (1) CA2835932C (https=)
ES (2) ES2700470T3 (https=)
PT (2) PT3199537T (https=)
TW (1) TWI635093B (https=)
WO (1) WO2012159047A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2835932C (en) 2011-05-19 2020-03-24 Gilead Sciences, Inc. Processes and intermediates for preparing anti-hiv agents
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
WO2018064071A1 (en) 2016-09-27 2018-04-05 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
SI3661937T1 (sl) 2017-08-01 2021-11-30 Gilead Sciences, Inc. Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb
PL3759109T3 (pl) 2018-02-26 2024-03-04 Gilead Sciences, Inc. Podstawione związki pirolizyny jako inhibitory replikacji hbv
CN114409706B (zh) * 2019-07-01 2023-11-28 上海医药工业研究院 一种苯基氢膦酸酯及其中间体的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US599431A (en) 1898-02-22 Clothes-wringer
GB835785A (en) * 1956-04-30 1960-05-25 Victor Chemical Works Method of making diaryl phosphites
MX3898E (es) * 1975-12-29 1981-09-10 Monsanto Co Procedimiento mejorado para la preparacion de triesteres de n-fosfonometilglicina
US4198355A (en) * 1977-03-28 1980-04-15 Mobil Oil Corporation Preparation of tertiary alkylphosphorodichloridite derivatives
US5459256A (en) * 1987-04-17 1995-10-17 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Lipophilic, aminohydrolase-activated prodrugs
HU906976D0 (en) 1989-11-13 1991-05-28 Bristol Myers Squibb Co Process for producing 2', 3'-didesoxy-2'-fluoarabinonucleoside analogues
US5672697A (en) * 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
CZ304734B6 (cs) 2000-07-21 2014-09-10 Gilead Sciences, Inc. Způsob přípravy 9-[2-(fosfonomethoxy)propyl]adeninu a 9-[2-(fosfonomethoxy)ethyl]adeninu
AU2003231765B9 (en) * 2002-04-26 2010-01-28 Gilead Sciences, Inc. Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such
JP2010535701A (ja) * 2003-04-25 2010-11-25 ギリアード サイエンシーズ, インコーポレイテッド 抗癌ホスホネートアナログ
EP2359833A1 (en) * 2003-04-25 2011-08-24 Gilead Sciences, Inc. Antiviral phosphonate analogs
RS51974B (sr) * 2004-07-16 2012-02-29 Gilead Sciences Inc. Antivirusna jedinjenja
ME03423B (me) * 2004-07-27 2020-01-20 Gilead Sciences Inc Fosfonatni analozi jedinjenja hiv inhibitora
CA2616314A1 (en) 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of hiv
WO2007109005A2 (en) * 2006-03-17 2007-09-27 Invista Technologies S.A R.L. Method for the purification of triorganophosphites by treatment with a basic additive
WO2008100447A2 (en) 2007-02-09 2008-08-21 Gilead Sciences, Inc. Nucleoside analogs for antiviral treatment
UA103329C2 (ru) * 2008-07-08 2013-10-10 Гилиад Сайенсиз, Инк. Соли соединений-ингибиторов вич
WO2011003018A2 (en) * 2009-07-01 2011-01-06 Cornell University Halogenated 2-deoxy-lactones, 2'-deoxy--nucleosides, and derivatives thereof
CA2835932C (en) 2011-05-19 2020-03-24 Gilead Sciences, Inc. Processes and intermediates for preparing anti-hiv agents

Also Published As

Publication number Publication date
NZ618939A (en) 2015-11-27
EP3450438A1 (en) 2019-03-06
US9296779B2 (en) 2016-03-29
US20120296076A1 (en) 2012-11-22
US20160340379A1 (en) 2016-11-24
EP3199537B1 (en) 2018-10-17
JP2016128459A (ja) 2016-07-14
EP2710019A1 (en) 2014-03-26
JP2017110025A (ja) 2017-06-22
PT2710019T (pt) 2017-07-21
AU2018200776B2 (en) 2019-10-03
AU2019226278A1 (en) 2019-09-26
TWI635093B (zh) 2018-09-11
JP2019089808A (ja) 2019-06-13
JP2014516968A (ja) 2014-07-17
US10196419B2 (en) 2019-02-05
AU2016208292A1 (en) 2016-08-11
AU2018200776A1 (en) 2018-02-22
AU2012255029B2 (en) 2016-04-28
JP6282295B2 (ja) 2018-02-21
US20180079773A1 (en) 2018-03-22
EP2710019B1 (en) 2017-05-03
ES2629913T3 (es) 2017-08-16
JP5951757B2 (ja) 2016-07-13
CA2835932A1 (en) 2012-11-22
JP6621772B2 (ja) 2019-12-18
AR086492A1 (es) 2013-12-18
PT3199537T (pt) 2019-01-17
EP3199537A1 (en) 2017-08-02
US8987437B2 (en) 2015-03-24
ES2700470T3 (es) 2019-02-15
US9783567B2 (en) 2017-10-10
US20190359644A1 (en) 2019-11-28
US20150203525A1 (en) 2015-07-23
AU2016208292B2 (en) 2018-02-22
AU2012255029A1 (en) 2013-05-02
WO2012159047A1 (en) 2012-11-22
TW201309715A (zh) 2013-03-01

Similar Documents

Publication Publication Date Title
AU2018200776B2 (en) Processes and intermediates for preparing anti-HIV agents
JP7441947B2 (ja) Mcl1阻害剤を調製するためのプロセス及び中間体
AU2013214879A1 (en) Methods and intermediates for preparing pharmaceutical agents
HK1196133A (en) Processes and intermediates for preparing anti-hiv agents
HK1196133B (en) Processes and intermediates for preparing anti-hiv agents
HK1239695B (en) Processes and intermediates for preparing anti-hiv agents
HK1239695A1 (en) Processes and intermediates for preparing anti-hiv agents
NZ618939B2 (en) Processes and intermediates for preparing anti-hiv agents
HK40004474A (en) Processes and intermediates for preparing anti-hiv agents
WO2022194924A1 (en) Chiral synthons for the synthesis of chiral phosphorothioates
HK40079919A (en) Processes and intermediates for preparing mcl1 inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170510

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241225

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241225

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241225

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260324

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260324